The present invention provides a method for fixing carbon dioxide gas as a carbonyl compound represented by formula (3) as depicted by FIG. 1 and comprising, purging of carbon dioxide in a solution of a nucleophile represented by the formula (1) in presence of a solvent at a temperature ranging from 40 Degree Celsius to 35 Degree Celsius, followed by adding a reagent at temperature ranging from 40 degree to 35 degree and thereafter adding another nucleophile represented by the formula (2) to obtain carbonyl compound represented by formula (3). The present invention can be advantageously used to obtain commercially important carbonyl compounds and clean unwanted carbon dioxide gas from the atmosphere and industrial effluents.

##STR00001##

The present invention provides a method for fixing carbon dioxide gas as a carbonyl compound represented by formula (3) as depicted by FIG. 1 and comprising, purging of carbon dioxide in a solution of a nucleophile represented by the formula (1) in presence of a solvent at a temperature ranging from 40 Degree Celsius to 35 Degree Celsius, followed by adding a reagent at temperature ranging from 40 degree to 35 degree and thereafter adding another nucleophile represented by the formula (2) to obtain carbonyl compound represented by formula (3). The present invention can be advantageously used to obtain commercially important carbonyl compounds and clean unwanted carbon dioxide gas from the atmosphere and industrial effluents.

##STR00001##

The invention relates to a process for the production of amide bonds, in particular peptide bonds, with the aid of novel amide linking reagents containing an anion of the formula (I), to the novel reagents, and to the preparation thereof.

The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

A compound of Formula [I] or a pharmaceutically acceptable salt thereof: ##STR00001##
wherein each symbol is defined as in the specification.

The present invention relates to polyurethane-urea elastomers with exceptional mechanical properties and enhanced elasticity based on molecular structure analysis. The present invention involves the synthesis of a polyurethane-urea elastomer using a combination of commercially available materials: (1) polyols with ultralow unsaturation and narrow polydispersity, (2) diisocyanates with symmetric steric conformation, and (3) bulky diamines between functional groups. The preparation method for the novel polyurethane-urea is disclosed. The subject elastomers have the highest reported elongation-at-break among known polyurethane elastomers.

The present invention relates to polyurethane-urea elastomers with exceptional mechanical properties and enhanced elasticity based on molecular structure analysis. The present invention involves the synthesis of a polyurethane-urea elastomer using a combination of commercially available materials: (1) polyols with ultralow unsaturation and narrow polydispersity, (2) diisocyanates with symmetric steric conformation, and (3) bulky diamines between functional groups. The preparation method for the novel polyurethane-urea is disclosed. The subject elastomers have the highest reported elongation-at-break among known polyurethane elastomers.

Disclosed herein is a salt, a crystalline anhydrous form, a hydrate, a solvate, or a co-crystal of a free base compound 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-[(2-hydroxyethanesulfonyl)amino]benzamide (Compound A); method of preparation, pharmaceutical compositions, and method of treating a disease mediated by a motor protein kinesin family member 18A (KIF18A) inhibition, wherein said disease is a neoplastic disease, including a cancer or a tumor.